Spironolactone (INN, BAN, USAN)[1]
Skeletal formula of spironolactone
Ball-and-stick model of the spironolactone molecule
Systematic (IUPAC) name
17-hydroxy-7α-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic acid, γ-lactone acetate
Clinical data
Pronunciation [2]
Trade names Aldactone
  • AU: B3
  • US: C (Risk not ruled out)
Legal status
Routes of
Pharmacokinetic data
Protein binding 90%+[3]
Metabolism Hepatic CYP450
Biological half-life 1.3-2 hours
Excretion Urine, bile
CAS Registry Number  Y
ATC code C03
PubChem CID:
DrugBank  Y
ChemSpider  Y
Chemical data
Formula C24H32O4S
Molecular mass 416.574 g/mol

Spironolactone, marketed under the brand name Aldactone among others, is a medication primarily used to treatment health system.[8] Spironolactone remains widely used for indications in which its antiandrogen effects are the intention of treatment.


  • Medical uses 1
    • Diuretic/antihypertensive 1.1
    • Antiandrogen 1.2
      • Acne in women 1.2.1
      • Hormone replacement therapy for trans women 1.2.2
      • Comparison with other antiandrogens 1.2.3
  • Side effects 2
    • Depression 2.1
    • Interactions 2.2
    • Contraindications 2.3
  • Pharmacology 3
    • Activity profile 3.1
    • Antimineralocorticoidic 3.2
    • Glucocorticoidic 3.3
    • Antiandrogenic 3.4
    • Progestogenic 3.5
    • Estrogenic 3.6
  • Pharmacokinetics 4
  • Spironolactone bodies 5
  • See also 6
  • References 7
  • External links 8

Medical uses


Spironolactone is used primarily to treat heart failure, edematous conditions such as nephrotic syndrome or ascites in patients with liver disease, essential hypertension, hypokalemia, secondary hyperaldosteronism (such as occurs with hepatic cirrhosis), and Conn's syndrome (primary hyperaldosteronism). On its own, spironolactone is only a weak diuretic because it primarily targets the distal nephron (collecting tubule), where only small amounts of sodium are reabsorbed, but it can be combined with other diuretics to increase efficacy. About one person in one hundred with hypertension has elevated levels of aldosterone; in these persons, the antihypertensive effect of spironolactone may exceed that of complex combined regimens of other antihypertensives since it targets the primary cause of the elevated blood pressure.

While loop diuretics remain first-line for most patients with heart failure, spironolactone has shown to reduce both morbidity and mortality in numerous studies and remains an important agent for treating fluid retention, edema, and symptoms of heart failure. Current recommendations from the American Heart Association are to use spironolactone in patients with NYHA Class II-IV heart failure who have a left ventricular ejection fraction of <35%.[9]

In a randomized evaluation which studied people with severe congestive heart failure, people treated with spironolactone were found to have a relative risk of death of 0.70 or an overall 30% relative risk reduction compared to the placebo group, indicating a significant Death and morbidity benefit of the drug. Patients in the study's intervention arm also had fewer symptoms of heart failure and were hospitalized less frequently.[10] Likewise, it has shown benefit for and is recommended in patients who recently suffered a heart attack and have an ejection fraction <40%, who develop symptoms consistent with heart failure, or have a history of diabetes mellitus. Spironolactone should be considered a good add-on agent, particularly in those patients "not" yet optimized on ACE inhibitors and beta-blockers.[11] Of note, a recent randomized, double-blinded study of spironolactone in patients with symptomatic heart failure with "preserved" ejection fraction (i.e. >45%) found no reduction in death from cardiovascular events, aborted cardiac arrest, or hospitalizations when spironolactone was compared to placebo.[12]

It is recommended that alternatives to spironolactone be considered if serum creatinine is >2.5 mg/dL (221µmol/L) in males or >2 mg/dL (176.8 µmol/L) in females, if glomerular filtration rate is below 30mL/min or with a serum potassium of >5.0 mEq/L given the potential for adverse events detailed elsewhere in this article. Doses should be adjusted according to the degree of renal function as well.[9]

According to systematic review, in patients with heart failure with preserved ejection fraction, treatment with spironolactone did not improve patient outcomes. This is based on the TOPCAT Trial examining this issue, which found that of those treated with placebo had a 20.4% incidence of negative outcome vs 18.6% incidence of negative outcome with spironolactone. However, because the p-value of the study was 0.14, and the unadjusted hazard ratio was 0.89 with a 95% confidence interval of 0.77 to 1.04, it is determined the finding had no statistical significance. Hence the finding that patient outcomes are not improved with use of spironolactone.[13]

Due to its antiandrogen properties, spironolactone can cause effects associated with low androgen levels and hypogonadism in males. For this reason, men are typically not prescribed spironolactone for any longer than a short period of time, e.g., for an acute exacerbation of heart failure. A newer drug, eplerenone, has been approved by the U.S. Food and Drug Administration for the treatment of heart failure, and lacks the antiandrogen effects of spironolactone. As such, it is far more suitable for men for whom long-term medication is being chosen. However, eplerenone may not be as effective as spironolactone or the related drug canrenone in reducing mortality from heart failure.[14]

The clinical benefits of spironolactone as a diuretic are typically not seen until 2–3 days after dosing begins. Likewise, the maximal antihypertensive effect may not be seen for 2–3 weeks.

Unlike with some other diuretics, potassium supplementation should not be administered while taking spironolactone, as this may cause dangerous elevations in serum potassium levels resulting in hyperkalemia and potentially deadly cardiac arrythmias.


Spironolactone is an antagonist of the androgen receptor (AR) as well as an inhibitor of androgen production. Due to the antiandrogenic effects that result from these actions, it is frequently used off-label to treat a variety of dermatological conditions in which androgens, such as testosterone and dihydrotestosterone (DHT), play a role. Some of these uses include androgenic alopecia in men (either at low doses or as a topical formulation) and women, and hirsutism, acne, and seborrhea in women.[15] Spironolactone is the most commonly used drug in the treatment of hirsutism in the United States.[16] Higher doses of spironolactone are not recommended in males due to the high risk of feminization and other side effects. Similarly, it is also commonly used to treat symptoms of hyperandrogenism in polycystic ovary syndrome.[17]

Acne in women

Because of spironolactone's antiandrogen effects, it can be quite effective in clearing severe acne conditions, such as cystic acne, caused by slightly elevated or elevated levels of testosterone in women. In reducing the levels of testosterone, excess oil that is naturally produced in the skin is also reduced. Though not the primary intended purpose of the medication, its ability to be helpful with problematic skin and acne conditions was discovered to be one of the beneficial side effects and has been quite successful. Oftentimes, for women treating acne, spironolactone is prescribed and paired with a birth control pill. A significant amount of patients have reported that they have seen positive results in the pairing of these two medications, although these results may not be seen for up to three months.

Hormone replacement therapy for trans women

Spironolactone is frequently used as a component of hormone replacement therapy in trans women, especially in the United States (where cyproterone acetate is not available), usually in addition to an estrogen. It is generally recommended to be prescribed at a dose of 100–200 mg per day for this purpose,[18][19] though it is frequently used at doses up to 300–400 mg in cases of treatment-resistant individuals, and doses as high as 600 mg have been used in some clinical studies, with additional benefits from the extreme dosage observed in some patients.[20] Spironolactone significantly depresses plasma testosterone levels, reducing them to female/castrate levels at sufficient doses and in combination with estrogen. The clinical response consists of, among other effects, decreased male pattern body hair, the induction of breast development, feminization in general, and lack of spontaneous erections.[20]

Comparison with other antiandrogens

There are few available options for antiandrogen therapy. Spironolactone, cyproterone acetate, and flutamide are some of the most well-known and widely-used drugs.[21] Compared to cyproterone acetate, spironolactone is considerably less potent as an antiandrogen by weight and binding affinity to the androgen receptor.[22][23] However, despite this, at the doses of which they are typically used, spironolactone and cyproterone acetate have been found to be generally about equivalent in terms of effectiveness for a variety of androgen-related conditions,[24] though, cyproterone acetate has shown a slight though non-statistically-significant advantage in some studies.[25][26] Also, it has been suggested that cyproterone acetate could be more effective in cases where androgen levels are more pronounced, though this has not been proven.[24]

Flutamide, another frequently used antiandrogen which is non-steroidal and a pure androgen receptor antagonist, though much less potent by weight and binding affinity than either spironolactone or cyproterone acetate,[27][28] has been found to be more effective than either of them as an antiandrogen when it is used at the typical treatment doses.[22][29][30] Unfortunately, the uses of both cyproterone acetate and flutamide have been associated with hepatotoxicity, which can be severe with flutamide and has resulted in the withdrawal of cyproterone acetate from the United States drug market for this indication. Bicalutamide is a more potent, safer, and more tolerable alternative to flutamide, but is relatively little-studied in the treatment of androgen-dependent conditions aside from prostate cancer, though it has been used to treat hirsutism with success. Gonadotropin-releasing hormone (GnRH) analogues are another very effective option for antiandrogen therapy, but have not been widely employed for this purpose due to their high cost and limited insurance coverage despite many now being available as generics.[19] As such, spironolactone may be the only practical, safe, available, and well-supported antiandrogen option in some cases.

In a study of the predictive markers for trans women requesting breast augmentation, there was a significantly higher rate of those treated with spironolactone requesting breast augmentation compared to other antiandrogens such as cyproterone acetate or GnRH analogues, which was interpreted by the study authors as being potentially indicative that spironolactone may result in poorer breast development in comparison.[31] This may be related to the fact that spironolactone has been regarded as a comparatively weak antiandrogen relative to other options.[32]

Side effects

The most common side effect of spironolactone is urinary frequency. Other general side effects include ataxia, drowsiness, dry skin, and rashes. Because it reduces androgen levels and blocks androgen receptors, spironolactone can, in males, cause breast tenderness, gynecomastia, and physical feminization in general, as well as testicular atrophy, reversible infertility, and sexual dysfunction, including loss of libido and erectile dysfunction.[33] In females, spironolactone can cause menstrual irregularities and breast tenderness and enlargement, likely due to a combination of its progestogenic and indirect estrogenic actions.[15]

The most important potential side effect of spironolactone is hyperkalemia, which, in severe cases, can be life-threatening. Spironolactone may put patients at a heightened risk for gastrointestinal issues like nausea, vomiting, diarrhea, cramping, and gastritis. In addition, there has been some evidence suggesting an association between use of the drug and bleeding from the stomach and duodenum, though a causal relationship between the two has not been established.[34] Also, it has been shown to be immunosuppressive in the treatment of sarcoidosis.[35]

Spironolactone may rarely cause more severe side effects such as anaphylaxis, renal failure, hepatotoxicity, agranulocytosis, DRESS syndrome, Stevens-Johnson Syndrome or toxic epidermal necrolysis.[36][37]


Spironolactone has been consistently shown to increase basal cortisol levels, as well as to increase the amount of cortisol secreted in response to stress and to produce higher cortisol levels in the dexamethasone suppression and corticotropin-releasing hormone stimulation tests.[38][39][40][41] These findings indicate increased activity of the HPA axis and increased activation of the GR with spironolactone treatment.[39][40][41] These effects of spironolactone are believed to be mediated by antagonism of the MR, which causes the body to upregulate the HPA axis and hence cortisol production in an attempt to increase mineralocorticoid levels and thereby restore homeostasis.[42][43]

Increased glucocorticoid activity, whether exogenous such as with a synthetic glucocorticoid like dexamethasone or endogenous as in with the elevated cortisol levels that occur in Cushing's syndrome, is well-known to be associated with depression.[41][44] In addition, elevated levels of cortisol are a hallmark of depression,[45] and the increase in cortisol levels caused by spironolactone has been reported to be higher in depressed patients relative to non-depressed controls.[38] Moreover, it has been proposed that MR dysfunction may underlie dysfunction of the HPA axis in depression, as well as of the pathology of depression in general.[40][41][46] As such, it is thought that there may be a risk of depression with spironolactone treatment as well as the potential for worsening of depression in already-depressed patients.[38][40][41]

In accordance, various clinical studies have reported depressive side effects and interference with antidepressant effectiveness with spironolactone treatment. In a study of a group of patients with mild chronic heart failure treated with 12.5–50 mg/daily spironolactone for three months, the drug was found to significantly worsen quality of life and depression scores.[47] In addition, a study of trans women found that antiandrogen treatment with spironolactone, as well as with cyproterone acetate (which is a direct agonist of the GR), were associated with significantly higher rates of depressive symptomology relative to treatment with gonadotropin-releasing hormone (GnRH) analogues (which are more pure antiandrogens and are considered not to have a significant risk of depression in trans women).[31]

A clinical study found that in patients being treated with amitriptyline for depression, co-administration of spironolactone impaired the antidepessant response to amitriptyline.[48] However, another study found that spironolactone (100 mg/day) added to escitalopram did not delay the onset of antidepressant effect (22 days versus 22 days for escitalopram alone), although the MR agonist fludrocortisone (0.2 mg/day) accelerated the onset of antidepressant effect (16 days versus 22 days for escitalopram alone).[46][49] In this study, spironolactone increased cortisol levels, and fludrocortisone decreased them, with non-responders showing higher cortisol levels relative to responders in the fludrocortisone group.[46][49] Spironolactone and fludrocortisone were only administered for the first three weeks of a five-week treatment period with escitalopram.[46][49] No differences in mean Hamilton Depression Rating Scale scores between any of the groups were observed at endpoint.[46][49]

Some conflicting data also exist, however. For instance, spironolactone has been used with effectiveness in the treatment of residual symptoms in euthymic bipolar disorder patients in limited case reports.[50][51] Improved stress resilience was reported in these patients treated with spironolactone, which is of relevance because stress can precipitate bipolar episodes.[51] In addition, spironolactone has been reported to improve mood in patients with premenstrual syndrome as well as bulimia nervosa patients in limited research.[46] Moreover, spironolactone reduces immobility in the forced swim test in animals treated with chronic corticosterone, a GR and MR agonist, indicating an antidepressant-like effect, at least in rodents.[39] In addition, blockade of the MR with spironolactone has been found to produce anxiolytic effects in diabetic mice as well as to potentiate the anxiolytic effects of diazepam.[52] Lastly, spironolactone was found to abolish the stress-induced enhancement of response inhibition after a single acute dose of 300 mg in humans.[53]


Spironolactone often increases serum potassium levels and can cause hyperkalemia, a very serious condition. Therefore, it is recommended that people using this drug avoid potassium supplements and salt substitutes containing potassium.[54] Physicians must be careful to monitor potassium levels in both males and females who are taking spironolactone as a diuretic, especially during the first twelve months of use and whenever the dosage is increased. Doctors may also recommend that some patients may be advised to limit dietary consumption of potassium-rich foods. However, recent data suggests that both potassium monitoring and dietary restriction of potassium intake is unnecessary in healthy young women taking spironolactone for acne.[55]

Research has suggested that spironolactone may be able to interfere with the effectiveness of antidepressant treatment. As the drug acts as an antagonist of the mineralocorticoid receptor, it is thought that it may reduce the effectiveness of certain antidepressants by interfering with normalization of the hypothalamic-pituitary-adrenal axis and increasing glucocorticoid levels.[56][46] However, other research contradicts this hypothesis and has suggested that spironolactone may actually produce antidepressant-like effects in animals.[57]

Spironolactone can also have numerous other interactions, most commonly with other cardiac and blood pressure medications.[58]


Spironolactone is considered Pregnancy Category C by the FDA and should not be taken by pregnant women due to the high risk of birth defects and feminization of male fetuses. Likewise, it has been found to be present in the breast milk of lactating mothers and, while the effects of spironolactone or its metabolites have not been extensively studied in breast-feeding infants, it is generally recommended that women also not take the drug while nursing.[15][58]

It should also be used with caution in patients with some neurological disorders, anuria, acute kidney injury, or significant impairment of renal excretory function with risk of hyperkalemia.[58]


Activity profile

Spironolactone is known to possess the following pharmacological activity:[59]

There is also evidence that spironolactone may block voltage-dependent Ca2+ channels.[64][65]

Spironolactone does not have significant affinity for either of the estrogen receptors (ERα or ERβ).


Spironolactone inhibits the effects of mineralocorticoids, namely, aldosterone, by displacing them from mineralocorticoid receptors (MR) in the cortical collecting duct of renal nephrons. This decreases the reabsorption of sodium and water, while limiting the excretion of potassium (A K+ sparing diuretic). The drug has a slightly delayed onset of action, and so it takes several days for diuresis to occur. This is because the MR is a nuclear receptor which works through regulating gene transcription and gene expression, in this case to decrease the production and expression of ENaC and ROMK electrolyte channels in the distal nephrons. In addition to direct antagonism of the MRs, the antimineralocorticoid effects of spironolactone may also in part be mediated by direct inactivation of steroid 11β-hydroxylase and aldosterone synthase (18-hydroxylase), enzymes involved in the biosynthesis of mineralocorticoids. If levels of mineralocorticoids are decreased then there are lower circulating levels to compete with spironolactone to influence gene expression as mentioned above.[66]


Spironolactone has been shown to inhibit steroid 11β-hydroxylase, an enzyme that is essential for the production of the glucocorticoid hormone cortisol. Because of this, glucocorticoid levels might be expected to be lowered, and hence, spironolactone might have some antiglucocorticoidic effects. In clinical practice however, this has not been found to be the case; spironolactone has actually been found to increase cortisol levels, both with acute and chronic administration. Research has shown that this is due to antagonism of the MR, which suppresses negative feedback on the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis positively regulates the secretion of adrenocorticotropic hormone (ACTH), which in turn signals the adrenal glands, the major source of corticosteroid biosynthesis in the body, to increase production of both mineralocorticoids and glucocorticoids. Therefore, by antagonizing the MR, spironolactone causes an increase in ACTH secretion and by extension an indirect rise in cortisol levels.[42][43] As such, any antiglucocorticoid activity of spironolactone via direct suppression of glucocorticoid synthesis (at the level of the adrenals) appears to be more than fully offset by its concurrent indirect stimulatory effects on glucocorticoid production.

Spironolactone weakly binds to and acts as an antagonist of the GR, showing antiglucocorticoid properties, but only at very high concentrations.[59][67][68]


Spironolactone mediates its antiandrogenic effects via multiple actions, including the following:

  • Direct blockade of androgens from interacting with the androgen receptor.[69][70] It should be noted however that spironolactone, similarly to other steroidal antiandrogens such as cyproterone acetate, is not a pure, or silent, antagonist of the androgen receptor, but rather a weak partial agonist with the capacity for both agonist and antagonist effects.[71][72][73] However, in the presence of significant enough levels of potent full agonists like testosterone and DHT,[73] the cases in which it is usually used even with regards to the "lower" relative levels present in females, spironolactone will behave similar to a pure antagonist. Nonetheless, there may still be a potential for spironolactone to produce androgenic effects (i.e. act as a receptor agonist) in the body at sufficiently high doses and/or in those with low enough endogenous androgen concentrations. As an example, one condition in which spironolactone is contraindicated is prostate cancer,[74] as the drug has been shown in vitro to significantly accelerate carcinoma growth in the absence of any other androgens, and was found to do so at the relatively high rate of approximately 32%, which was about 35% that of DHT (thus also indicating that its potential intrinsic activity at the androgen receptor may be somewhere around one-third that of endogenous full agonists).[71] In accordance, a case report described significant worsening of prostate cancer with spironolactone treatment in a patient with the disease, leading the authors to conclude that spironolactone has the potential for androgenic effects and that it should perhaps be considered to be a selective androgen receptor modulator (SARM).[75]
  • Inhibition of 5α-reductase, the enzyme responsible for converting testosterone into the 3- to 10-fold more potent androgen dihydrotestosterone (DHT). However, there is conflicting data on the ability of spironolactone to affect this enzyme. An in vitro study of the effect of spironolactone on prostate tissue 5α-reductase activity found no change even with very high concentrations of the drug.[69] In contrast, another study, after one month of treatment of spironolactone at a dose of 100 mg per day via the oral route, found a significant in vivo inhibitory effect of spironolactone on genital skin 5α-reductase activity in hirsute women as well as an inhibitory effect of the drug on 5α-reductase activity in normal genital skin in vitro, and concluded that spironolactone directly inhibits the 5α-reductase enzyme and that the property could play a role of the beneficial effects of the drug on hirsutism.[79] However, another study of spironolactone in hirsute women, after 6 months of treatment at the same dose (100 mg/d orally), found no significant effects of the drug on the serum ratios of testosterone to DHT and its metabolites—a reliable marker of 5α-reductase activity—whereas significant changes were found with 5 mg per day oral finasteride, a well-established 5α-reductase inhibitor.[80] Finally, yet another study of spironolactone in hirsute women, after 3 months of treatment at a higher dose of 200 mg per day orally, did report significant changes, in the same metabolic markers of 5α-reductase activity.[81] In summation then, whether spironolactone actually inhibits 5α-reductase to some clinical end-point or not and how it may do so remain unclear. It can be deduced from comparison studies, however, that if it does have an effect at reducing hirsutism, it is not as effective as more potent and selective 5α-reductase inhibitors like finasteride. Supporting this conclusion is another trial in which the combination of 100 mg/d spironolactone and 5 mg/d finasteride was found to be significantly more effective than spironolactone alone in the treatment of hirsutism in women.[82]
  • Acceleration of the rate of metabolism/clearance of testosterone by enhancing the rate of peripheral conversion of testosterone into estradiol.[77]


Spironolactone has weak progestogenic properties.[28][83] Its actions in this regard are a result of direct agonist activity at the progesterone receptor, but with a half-maximal potency approximately one-tenth that of its activity at the androgen receptor.[59] Spironolactone's progestogenic actions are thought to be responsible for some of its side effects,[84] including the menstrual irregularities seen in women and the undesirable serum lipid profile changes that are seen at higher doses.[27][85][86] They may also serve to augment the gynecomastia caused by the estrogenic effects of spironolactone,[87] as progesterone is known to play a role in breast development.[88]


Spironolactone has some indirect estrogenic effects which it mediates via several actions, including the following:

  • By acting as an antiandrogen, as androgens suppress both estrogen production and action.[70][89]
  • Displacement of estrogens from sex hormone-binding globulin (SHBG).[76] This occurs because spironolactone binds to SHBG at a relatively high rate, as do endogenous estrogens and androgens, but estrogens like estradiol and estrone are more easily displaced than are androgens like testosterone. As a result, spironolactone blocks relatively more estrogens from interacting with SHBG than androgens, resulting in a higher ratio of free estrogens to free androgens.[90]
  • Inhibition of the conversion of estradiol to estrone, resulting in an increase in the ratio of estradiol to estrone.[91] This is important because estradiol is approximately 10 times as potent as estrone as an estrogen.[92]
  • Enhancement of the rate of peripheral conversion of testosterone to estradiol, thus further lowering testosterone levels and increasing estradiol levels.[77]


Spironolactone has a very short half-life.[84] It is rapidly and extensively converted (>80%) into canrenone/canrenoic acid,[93][94] and canrenone is its major circulating metabolite.[95] Canrenone is an antagonist of the MR similarly to spironolactone,[93] but is more potent in comparison.[96] In addition, canrenone inhibits steroidogenic enzymes such as 11β-hydroxylase, cholesterol side-chain cleavage enzyme, 17α-hydroxylase, and 21-hydroxylase similarly to spironolactone, but once again is more potent in doing so in comparison.[95] Based on the above, the antimineralocorticoid effects of spironolactone are considered to be largely due to canrenone.[93]

In vitro, canrenone binds to and blocks the androgen receptor (AR).[70] However, relative to spironolactone, canrenone is described as having very weak affinity to the androgen receptor.[32] In accordance, replacement of spironolactone with canrenone in male patients has been found to reverse spironolactone-induced gynecomastia, suggesting that canrenone is comparatively much less potent in vivo as an antiandrogen.[70] As such, based on the above, the antiandrogen effects of spironolactone are considered to be largely due to its unchanged form, rather than due to metabolization into canrenone, or possibly due to other metabolites.[70][94][97]

Canrenone and 7α-methylthiospironolactone have been determined to be the major hepatic metabolites of spironolactone.[98][99] More recently however, it has been suggested that 7α-methylthiospironolactone may actually be the most important active metabolite of spironolactone.[99] It occurs at higher plasma levels than canrenone, and has a higher affinity for the MR.[99] 7α-Methylthiospironolactone has been relatively little-studied, and relatively little overall is known about it.[98] Other known metabolites of spironolactone include 7α-thiospironolactone, 6β-hydroxy-7α-methylthiospironolactone, the 7α-methyl ethyl ester of spironolactone, and the 6β-hydroxy-7α-methyl ethyl ester of spironolactone.[100]

Spironolactone has an onset of action of about 2–3 hours after taking the first dose, with a half-life of about 1–2 hours. It is highly plasma protein bound. Spironolactone is metabolized by the liver, from which it is partially eliminated with the majority being handled by the kidneys. Minimal amounts are handled by biliary excretion.[3] The bioavailability of spironolactone improves significantly when it is taken with food.[101][102]

Spironolactone induces the enzyme CYP3A4, which can result in interactions with various drugs.[103] It is not metabolized by CYP3A4, unlike the related drug eplerenone.[104]

Spironolactone bodies

Micrograph of an adrenal gland spironolactone bodies. H&E stain.

Long-term administration of spironolactone gives the histologic characteristic of spironolactone bodies in the adrenal cortex. Spironolactone bodies are eosinophilic, round, concentrically laminated cytoplasmic inclusions surrounded by clear halos in preparations stained with hematoxylin and eosin.[105]

See also


  1. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 1614.  
  2. ^ "Spironolactone: MedlinePlus Drug Information". Retrieved 2012-06-20. 
  3. ^ a b Harry G. Brittain (26 November 2002). Analytical Profiles of Drug Substances and Excipients. Academic Press. p. 309.  
  4. ^ a b c d "Spironolactone". The American Society of Health-System Pharmacists. Retrieved Oct 24, 2015. 
  5. ^ Maizes, Victoria (2015). Integrative Women's Health (2 ed.). p. 746.  
  6. ^ Camille Georges Wermuth (24 July 2008). The Practice of Medicinal Chemistry. Academic Press. p. 34.  
  7. ^ Marshall Sittig (1988). Pharmaceutical Manufacturing Encyclopedia. William Andrew. p. 1385.  
  8. ^ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014. 
  9. ^ a b Yancy, CW; Jessup, M; Bozkurt, B; Butler, J; Casey DE, Jr; Drazner, MH; Fonarow, GC; Geraci, SA; Horwich, T; Januzzi, JL; Johnson, MR; Kasper, EK; Levy, WC; Masoudi, FA; McBride, PE; McMurray, JJ; Mitchell, JE; Peterson, PN; Riegel, B; Sam, F; Stevenson, LW; Tang, WH; Tsai, EJ; Wilkoff, BL; American College of Cardiology, Foundation; American Heart Association Task Force on Practice, Guidelines (Oct 15, 2013). "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.". Journal of the American College of Cardiology 62 (16): e147–239.  
  10. ^ Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999). "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators". N Engl J Med 341 (10): 709–17.  
  11. ^ Yancy CW, Jessup M, Bozkurt B, et al. (October 2013). "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". J. Am. Coll. Cardiol. 62 (16): e147–239.  
  12. ^ Pitt, B; Pfeffer, MA; Assmann, SF; Boineau, R; Anand, IS; Claggett, B; Clausell, N; Desai, AS; Diaz, R; Fleg, JL; Gordeev, I; Harty, B; Heitner, JF; Kenwood, CT; Lewis, EF; O'Meara, E; Probstfield, JL; Shaburishvili, T; Shah, SJ; Solomon, SD; Sweitzer, NK; Yang, S; McKinlay, SM; TOPCAT, Investigators (Apr 10, 2014). "Spironolactone for heart failure with preserved ejection fraction.". The New England Journal of Medicine 370 (15): 1383–92.  
  13. ^ Pitt B. et. al. (2014). "Spironolactone for Heart Failure with Preserved Ejection Fraction". N Engl J Med 370 (15): 1383–1392.  
  14. ^ Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N, Mukherjee D (2012). "Eplerenone is not superior to older and less expensive aldosterone antagonists". Am. J. Med. 125 (8): 817–25.  
  15. ^ a b c Hughes BR, Cunliffe WJ (May 1988). "Tolerance of spironolactone". The British Journal of Dermatology 118 (5): 687–91.  
  16. ^ Victor R. Preedy (1 January 2012). Handbook of Hair in Health and Disease. Springer Science & Business Media. pp. 132–.  
  17. ^ Loy R, Seibel MM (December 1988). "Evaluation and therapy of polycystic ovarian syndrome". Endocrinology and Metabolism Clinics of North America 17 (4): 785–813.  
  18. ^ The World Professional Association for Transgender Health (WPATH) (2011). "Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People" (PDF). Retrieved 2012-05-27. 
  19. ^ a b Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. (September 2009). "Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline". The Journal of Clinical Endocrinology and Metabolism 94 (9): 3132–54.  
  20. ^ a b Prior JC, Vigna YM, Watson D (February 1989). "Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism". Archives of Sexual Behavior 18 (1): 49–57.  
  21. ^ Reismann P, Likó I, Igaz P, Patócs A, Rácz K (August 2009). "Pharmacological options for treatment of hyperandrogenic disorders". Mini Reviews in Medicinal Chemistry 9 (9): 1113–26.  
  22. ^ a b Robert S. Haber; Dowling Bluford Stough (2006). Hair Transplantation. Elsevier Health Sciences. p. 6.  
  23. ^ Peter Greaves (12 April 2012). Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation. Academic Press. p. 621.  
  24. ^ a b Andrea Dunaif (19 February 2008). Polycystic Ovary Syndrome: Current Controversies, from the Ovary to the Pancreas. Humana Press. p. 301.  
  25. ^ Gökmen O, Senöz S, Gülekli B, Işik AZ (August 1996). "Comparison of four syndrome". Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology 10 (4): 249–55.  
  26. ^ O'Brien RC, Cooper ME, Murray RM, Seeman E, Thomas AK, Jerums G (May 1991). "Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism". The Journal of Clinical Endocrinology and Metabolism 72 (5): 1008–13.  
  27. ^ a b Douglas T. Carrell (12 April 2010). Reproductive Endocrinology and Infertility: Integrating Modern Clinical and Laboratory Practice. Springer. p. 163.  
  28. ^ a b c Desai; Meena P.; Vijayalakshmi Bhatia & P.S.N. Menon (1 January 2001). Pediatric Endocrine Disorders. Orient Blackswan. p. 167.  
  29. ^ Allan H. Goroll; Albert G. Mulley (27 January 2009). Primary Care Medicine: Office Evaluation and Management of the Adult Patient. Lippincott Williams & Wilkins. p. 1264.  
  30. ^ Grigoriou O, Papadias C, Konidaris S, Antoniou G, Karakitsos P, Giannikos L (April 1996). "Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial". Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology 10 (2): 119–23.  
  31. ^ a b Seal, L. J.; Franklin, S.; Richards, C.; Shishkareva, A.; Sinclaire, C.; Barrett, J. (2012). "Predictive Markers for Mammoplasty and a Comparison of Side Effect Profiles in Transwomen Taking Various Hormonal Regimens". The Journal of Clinical Endocrinology & Metabolism 97 (12): 4422–4428.  
  32. ^ a b H.J.T. Coelingh Benni; H.M. Vemer (15 December 1990). Chronic Hyperandrogenic Anovulation. CRC Press. pp. 152–.  
  33. ^ "Spironolactone and endocrine dysfunction". Annals of Internal Medicine 85 (5): 630–6. November 1976.  
  34. ^ Verhamme K, Mosis G, Dieleman JP, et al. (2006). "Spironolactone and risk of upper gastrointestinal events: population based case-control study". Brit Med J 333 (7563): 330–3.  
  35. ^ Wandelt-Freerksen E. (1977). "Aldactone in the treatment of sarcoidosis of the lungs". JZ Erkr Atmungsorgane. 149 (1): 156–9.  
  36. ^ http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258786.htm
  37. ^ online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7699#f_adverse-reactions
  38. ^ a b c Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H (2003). "Mineralocorticoid receptor function in major depression". Arch. Gen. Psychiatry 60 (1): 24–8.  
  39. ^ a b c Cornelisse S, Joëls M, Smeets T (2011). "A randomized trial on mineralocorticoid receptor blockade in men: effects on stress responses, selective attention, and memory". Neuropsychopharmacology 36 (13): 2720–8.  
  40. ^ a b c d Heuser I, Deuschle M, Weber B, Stalla GK, Holsboer F (2000). "Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone". Psychoneuroendocrinology 25 (5): 513–8.  
  41. ^ a b c d e Thomas Steckler; N.H. Kalin; J.M.H.M. Reul (25 February 2005). Handbook of Stress and the Brain Part 2: Stress: Integrative and Clinical Aspects: Stress: Integrative and Clinical Aspects. Elsevier. pp. 444–.  
  42. ^ a b Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H (September 1998). "The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans". The Journal of Clinical Endocrinology and Metabolism 83 (9): 3339–45.  
  43. ^ a b Otte C, Moritz S, Yassouridis A, et al. (January 2007). "Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition". Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology 32 (1): 232–8.  
  44. ^ Robert G. Lahita (9 June 2004). Systemic Lupus Erythematosus. Academic Press. pp. 797–.  
  45. ^ Thomas E. Schlaepfer; Charles B. Nemeroff (2012). Neurobiology of Psychiatric Disorders. Elsevier. pp. 213–.  
  46. ^ a b c d e f g Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K, et al. (2010). "Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study". J Psychiatr Res 44 (6): 339–46.  
  47. ^ Macdonald, J E (2004). "Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment". Heart 90 (7): 765–770.  
  48. ^ Holsboer, F (2000). "The Corticosteroid Receptor Hypothesis of Depression". Neuropsychopharmacology 23 (5): 477–501.  
  49. ^ a b c d Steroid Receptors: Advances in Research and Application: 2011 Edition. ScholarlyEditions. 9 January 2012. pp. 300–.  
  50. ^ Hendler NH (1978). "Spironolactone prophylaxis in manic-depressive disease". J. Nerv. Ment. Dis. 166 (7): 517–20.  
  51. ^ a b Juruena MF, Gama CS, Berk M, Belmonte-de-Abreu PS (2009). "Improved stress response in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series". J. Psychopharmacol. (Oxford) 23 (8): 985–7.  
  52. ^ López-Rubalcava C, Paez-Martinez N, Oikawa J (2013). "Blockade of corticosteroid receptors induces anxiolytic-like effects in streptozotocin-induced diabetic mice, and synergizes with diazepam". Behav Pharmacol 24 (4): 320–7.  
  53. ^ Schwabe L, Höffken O, Tegenthoff M, Wolf OT (2013). "Stress-induced enhancement of response inhibition depends on mineralocorticoid receptor activation". Psychoneuroendocrinology 38 (10): 2319–26.  
  54. ^ "Advisory Statement" (PDF). Klinge Chemicals / LoSalt. Archived from the original (pdf) on 2006-11-15. Retrieved 2007-03-15. 
  55. ^ Plovanich M, Weng QY, Mostaghimi A (2015). "Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne". JAMA Dermatology.  
  56. ^ Holsboer, F. The Rationale for Corticotropin-Releasing Hormone Receptor (CRH-R) Antagonists to Treat Depression and Anxiety. J. Psychiatr. Res. 33, 181–214 (1999).
  57. ^ Mostalac-Preciado CR, de Gortari P, López-Rubalcava C (September 2011). "Antidepressant-like effects of mineralocorticoid but not glucocorticoid antagonists in the lateral septum: interactions with the serotonergic system". Behav. Brain Res. 223 (1): 88–98.  
  58. ^ a b c http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/012151s062lbl.pdf
  59. ^ a b c Fagart J, Hillisch A, Huyet J, et al. (September 2010). "A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule". The Journal of Biological Chemistry 285 (39): 29932–40.  
  60. ^ Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H (1998). "Inhibition and induction of human cytochrome P450 (CYP) enzymes" (PDF). Xenobiotica 28 (12): 1203–53.  
  61. ^ Rigalli JP, Ruiz ML, Perdomo VG, Villanueva SS, Mottino AD, Catania VA (July 2011). "Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells". Toxicology 285 (1-2): 18–24.  
  62. ^ Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (September 1998). "The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions". J. Clin. Invest. 102 (5): 1016–23.  
  63. ^ Christians U, Schmitz V, Haschke M (December 2005). "Functional interactions between P-glycoprotein and CYP3A in drug metabolism". Expert Opin Drug Metab Toxicol 1 (4): 641–54.  
  64. ^ Sorrentino R, Autore G, Cirino G, d'Emmanuele de Villa Bianca R, Calignano A, Vanasia M, et al. (2000). "Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings.". J Cardiovasc Pharmacol 36 (2): 230–235.  
  65. ^ Bendtzen, K.; Hansen, P. R.; Rieneck, K. (2003). "Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis". Clinical and Experimental Immunology 134 (1): 151158.  
  66. ^ Cheng SC, Suzuki K, Sadee W, Harding BW (October 1976). "Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria". Endocrinology 99 (4): 1097–106.  
  67. ^ Campen TJ, Fanestil DD (1982). "Spironolactone: a glucocorticoid agonist or antagonist?". Clin Exp Hypertens A 4 (9-10): 1627–36.  
  68. ^ Couette B, Marsaud V, Baulieu EE, Richard-Foy H, Rafestin-Oblin ME (1992). "Spironolactone, an aldosterone antagonist, acts as an antiglucocorticosteroid on the mouse mammary tumor virus promoter". Endocrinology 130 (1): 430–6.  
  69. ^ a b Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J (July 1975). "Antiandrogenic effect of spirolactones: mechanism of action". Endocrinology 97 (1): 52–8.  
  70. ^ a b c d e f Donald W. Seldin; Gerhard H. Giebisch (4 September 1997). Diuretic agents: clinical physiology and pharmacology. Academic Press. p. 630.  
  71. ^ a b Luthy IA, Begin DJ, Labrie F (November 1988). "Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture". Journal of Steroid Biochemistry 31 (5): 845–52.  
  72. ^ Térouanne B, Tahiri B, Georget V, et al. (February 2000). "A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects". Molecular and Cellular Endocrinology 160 (1-2): 39–49.  
  73. ^ a b Marc A. Fritz; Leon Speroff (20 December 2010). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. p. 80.  
  74. ^ Attard G, Reid AH, Olmos D, de Bono JS (June 2009). "Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven". Cancer Research 69 (12): 4937–40.  
  75. ^ Sundar S, Dickinson PD (2012). "Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate". BMJ Case Rep 2012.  
  76. ^ a b Haynes BA, Mookadam F (August 2009). "Male gynecomastia".  
  77. ^ a b c Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH (October 1977). "Pathophysiology of spironolactone-induced gynecomastia". Annals of Internal Medicine 87 (4): 398–403.  
  78. ^ Masahashi T, Wu MC, Ohsawa M, et al. (January 1986). "Spironolactone therapy for hyperandrogenic anovulatory women--clinical and endocrinological study". Nihon Sanka Fujinka Gakkai Zasshi 38 (1): 95–101.  
  79. ^ Serafini PC, Catalino J, Lobo RA (August 1985). "The effect of spironolactone on genital skin 5 alpha-reductase activity". Journal of Steroid Biochemistry 23 (2): 191–4.  
  80. ^ Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA (January 1995). "A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women". The Journal of Clinical Endocrinology and Metabolism 80 (1): 233–8.  
  81. ^ Miles RA, Cassidenti DL, Carmina E, Gentzschein E, Stanczyk FZ, Lobo RA (October 1992). "Cutaneous application of an androstenedione gel as an in vivo test of 5 alpha-reductase activity in women". Fertility and Sterility 58 (4): 708–12.  
  82. ^ Keleştimur F, Everest H, Unlühizarci K, Bayram F, Sahin Y (March 2004). "A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism". European Journal of Endocrinology / European Federation of Endocrine Societies 150 (3): 351–4.  
  83. ^ Schane, H. P.; Potts, G. O. (1978). "Oral Progestational Activity of Spironolactone". Journal of Clinical Endocrinology & Metabolism 47 (3): 691694.  
  84. ^ a b Delyani, John A (2000). "Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology". Kidney International 57 (4): 14081411.  
  85. ^ Shlomo Melmed; Kenneth S. Polonsky; P. Reed MD Larsen; Henry M. Kronenberg (31 May 2011). Williams Textbook of Endocrinology E-Book: Expert Consult. Elsevier Health Sciences. p. 2057.  
  86. ^ Nakhjavani M, Hamidi S, Esteghamati A, Abbasi M, Nosratian-Jahromi S, Pasalar P (October 2009). "Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism". British Journal of Clinical Pharmacology 68 (4): 634–7.  
  87. ^ Eckhard Ottow; Hilmar Weinmann (9 July 2008). Nuclear Receptors As Drug Targets. John Wiley & Sons. p. 410.  
  88. ^ Anderson E (2002). "The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis". Breast Cancer Research : BCR 4 (5): 197–201.  
  89. ^ Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA (September 2000). "Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression".  
  90. ^ Braunstein GD (September 2007). "Clinical practice. Gynecomastia". The New England Journal of Medicine 357 (12): 1229–37.  
  91. ^ Satoh T, Itoh S, Seki T, Itoh S, Nomura N, Yoshizawa I (October 2002). "On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production". The Journal of Steroid Biochemistry and Molecular Biology 82 (2-3): 209–16.  
  92. ^ Ruggiero RJ, Likis FE (2002). "Estrogen: physiology, pharmacology, and formulations for replacement therapy". Journal of Midwifery & Women's Health 47 (3): 130–8.  
  93. ^ a b c Michelle A. Clark; Richard A. Harvey; Richard Finkel; Jose A. Rey, Karen Whalen (15 December 2011). Pharmacology. Lippincott Williams & Wilkins. pp. 286–.  
  94. ^ a b Armanini D, Karbowiak I, Goi A, Mantero F, Funder JW (1985). "In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay". Clin. Endocrinol. (Oxf) 23 (4): 341–7.  
  95. ^ a b Colby HD (1981). "Chemical suppression of steroidogenesis". Environ. Health Perspect. 38: 119–27.  
  96. ^ Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ (2013). "The role of mineralocorticoid receptor function in treatment-resistant depression". J. Psychopharmacol. (Oxford) 27 (12): 1169–79.  
  97. ^ Andriulli A, Arrigoni A, Gindro T, Karbowiak I, Buzzetti G, Armanini D (1989). "Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy". Digestion 44 (3): 155–62.  
  98. ^ a b Cashman, John R.; Pena, Sandra (1989). "Canrenone formation via general-base-catalyzed elimination of 7.alpha.-(methylthio)spironolactone S-oxide". Chemical Research in Toxicology 2 (2): 109–113.  
  99. ^ a b c Agusti G, Bourgeois S, Cartiser N, Fessi H, Le Borgne M, Lomberget T (2013). "A safe and practical method for the preparation of 7α-thioether and thioester derivatives of spironolactone". Steroids 78 (1): 102–7.  
  100. ^ Gyorgy Szasz; Zsuzsanna Budvari-Barany (19 December 1990). Pharmaceutical Chemistry of Antihypertensive Agents. CRC Press. pp. 91–.  
  101. ^ Overdiek HW, Merkus FW (November 1986). "Influence of food on the bioavailability of spironolactone". Clinical Pharmacology and Therapeutics 40 (5): 531–6.  
  102. ^ Melander A, Danielson K, Scherstén B, Thulin T, Wåhlin E (July 1977). "Enhancement by food of canrenone bioavailability from spironolactone". Clinical Pharmacology and Therapeutics 22 (1): 100–3.  
  103. ^ Mellar P. Davis (28 May 2009). Opioids in Cancer Pain. OUP Oxford. pp. 222–.  
  104. ^ Blaine T. Smith; Paramount Wellness Institute Brian Luke Seaward, Ph.D.; Visiting Professor University of Oklahoma College of Pharmacy Blaine T Smith (1 November 2014). Pharmacology for Nurses. Jones & Bartlett Publishers. pp. 169–.  
  105. ^ Aiba M, Suzuki H, Kageyama K, et al. (June 1981). "Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa". Am. J. Pathol. 103 (3): 404–10.  

External links

  • nih.gov information site
  • Aldactone patient info leaflet